Nimodipine

Structural formula
Structural formula without stereochemistry - 1: 1 mixture ( racemate )
General
Non-proprietary name	Nimodipine
other names	2,6-Dimethyl-4- (3-nitrophenyl) -1,4-dihydropyridine-3,5-dicarboxylic acid-3-isopropyl ester-5- (2-methoxyethyl) ester ( IUPAC )
Molecular formula	C 21 H 26 N 2 O 7
Brief description	colorless solid
External identifiers / databases
CAS number 66085-59-4 EC number 266-127-0 ECHA InfoCard 100.060.096 PubChem 4497 DrugBank DB00393 Wikidata Q421429
Drug information
ATC code	C08 CA06
Drug class	Calcium antagonist
properties
Molar mass	418.44 g · mol -1
Physical state	firmly
solubility	almost insoluble in water
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS labeling of hazardous substances Caution H and P phrases H: 312-332 P: 280
Toxicological data	2738 mg kg −1 ( LD 50 ,  rat ,  oral )
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Nimodipine ( trade name : Nimotop ^® , manufacturer: Bayer ) is a medicinal substance ( calcium channel blocker ) from the group of 1,4-dihydropyridines .

By blocking calcium channels, it has a relaxing effect on vascular muscles, supposedly especially in the brain. It is used after subarachnoid hemorrhages to prevent vasospasms (vascular spasms) and thus to ensure cerebral blood flow. (Vascular spasms of this kind can be triggered by serotonin and hemoglobin breakdown products.)

Nimodipine is also approved for age-related brain disorders ( nootropic ).

Stereochemistry

Nimodipine contains a stereocenter and consists of two enantiomers, more precisely two atropisomers . This is a racemate , i.e. a 1: 1 mixture of ( R ) - and ( S ) -form:

Enantiomers of nimodipine
CAS number: 77940-92-2	CAS number: 77940-93-3

Individual evidence

1. ↑ ^{a b c d e} data sheet Nimodipine from Sigma-Aldrich , accessed on April 16, 2011 ( PDF ).
2. ↑ Red List online, as of October 2009.
3. ↑ AM comp. d. Switzerland, as of October 2009.
4. ↑ AGES-PharmMed, as of October 2009.
5. ↑ Rote Liste Service GmbH (Ed.): Rote Liste 2017 - drug directory for Germany (including EU approvals and certain medical devices) . Rote Liste Service GmbH, Frankfurt / Main, 2017, edition 57, ISBN 978-3-946057-10-9 , p. 204.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !